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Familial Adenomatous Polyposis (FAP) is a well
described autosomal dominant syndrome, whereby indi-
viduals develop multiple (up to thousands) of adenoma-
tous polyps in the large bowel, conferring an extremely
high risk of bowel cancer if left untreated.
If the family specific mutation is known, genetic test-
ing can be offered to at risk individuals to determine the
need for endoscopic surveillance. Guidelines suggest
starting endoscopic surveillance from the early teens.
Most individuals with FAP undergo colectomy between
the ages of 15 and 25 years [1].
Recent studies have shown that many adults with FAP
want their children to undergo genetic testing before the
age of 12 years, the approximate age at which genetic test-
ing is usually offered in Australia [2,3].
Health professionals working in cancer genetics in Aus-
tralia and New Zealand completed a web based survey
aimed at examining their attitudes and experiences
regarding genetic testing for young people at risk of FAP.
Findings from the survey provide an insight into the
views and practices of health professionals working in
this area, including: the age at which they believe testing
young people is most appropriate; their experiences
regarding parental requests for testing of younger chil-
dren; and whether the option of prenatal testing and pre-
implantation genetic diagnosis is routinely discussed with
individuals who have FAP and are also of child bearing
age. These have important implications for clinical prac-
tice within the Australian cancer genetics community.
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